Subcutaneous insulin B:9-23/IFA immunisation induces Tregs that control late-stage prediabetes in NOD mice through IL-10 and IFNγ
Open Access
- 20 May 2010
- journal article
- research article
- Published by Springer Nature in Diabetologia
- Vol. 53 (9) , 1958-1970
Abstract
Aims/hypothesis Subcutaneous immunisation with the 9–23 amino acid region of the insulin B chain (B:9-23) in incomplete Freund’s adjuvant (IFA) can protect the majority of 4- to 6-week-old prediabetic NOD mice and is currently in clinical trials. Here we analysed the effect of B:9-23/IFA immunisation at later stages of the disease and the underlying mechanisms. Methods NOD mice were immunised once s.c. with B:9-23/IFA at 5 or 9 weeks of age, or when blood glucose reached 10 mmol/l or higher. Diabetes incidence was followed in addition to variables such as regulatory T cell (Treg) induction, cytokine production (analysed by Elispot) and emergence of pathogenic CD8+/NRP-V7+ cells. Results A single B:9-23/IFA immunisation protected the majority of NOD mice at advanced stages of insulitis, but not after blood glucose reached 13.9 mmol/l. It increased Treg numbers and lost its protective effect after IFNγ or IL-10 neutralisation, but not in the absence of IL-4. CD4+CD25+ and to a lesser extent IFNγ-producing cells from mice protected by B:9-23/IFA induced tolerance upon transfer into new NOD animals, indicating that a dominant Treg-mediated effect was operational. Reduced numbers of CD8+/NRP-V7+ memory T cells coincided with protection from the disease. Conclusions/interpretation Protection from diabetes after B:9-23/IFA immunisation cannot be achieved once diabetes is fully established, but can be achieved at most prediabetic stages of the disease. Protection is mediated by Tregs that require IFNγ and IL-10. These findings should provide important guidance for ongoing human trials, especially for the development of suitable T cell biomarkers.Keywords
This publication has 49 references indexed in Scilit:
- Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapyJournal of Autoimmunity, 2010
- Regulatory Function of a Novel Population of Mouse Autoantigen-Specific Foxp3− Regulatory T Cells Depends on IFN-γ, NO, and Contact with Target CellsPLOS ONE, 2009
- TGF-β: A Master of All T Cell TradesCell, 2008
- Innocuous IFNγ induced by adjuvant-free antigen restores normoglycemia in NOD mice through inhibition of IL-17 productionJournal of Experimental Medicine, 2008
- Priming and effector dependence on insulin B:9–23 peptide in NOD islet autoimmunityJournal of Clinical Investigation, 2007
- Foxp3 in control of the regulatory T cell lineageNature Immunology, 2007
- Moving towards efficient therapies in type 1 diabetes: To combine or not to combine?Autoimmunity Reviews, 2007
- Translational Mini-Review Series on Type 1 Diabetes: Immune-based therapeutic approaches for type 1 diabetesClinical and Experimental Immunology, 2007
- Translational Mini-Review Series on Type 1 Diabetes: Systematic analysis of T cell epitopes in autoimmune diabetesClinical and Experimental Immunology, 2007
- Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing TregsJournal of Clinical Investigation, 2006